Monte Rosa Therapeutics, Inc. - ROE
GLUE
Price:
$18.31
Market Cap:
$1.19B
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and ...[Read more]
Industry
Biotechnology
IPO Date
2021-06-24
Stock Exchange
NASDAQ
Ticker
GLUE
PE Ratio
[-12.37]
ROE
[-40.99%]
Current Ratio
[9.54]
Dividend Yield
[0%]
Enterprise Value
[1.07B]
Dividend History
The ROE as of June 2026 (TTM) for Monte Rosa Therapeutics, Inc. (GLUE) is -40.99%
According to Monte Rosa Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -40.99%. This represents a change of 273.23% compared to the average of -10.98% of the last 4 quarters.
Monte Rosa Therapeutics, Inc. (GLUE) Historical ROE (quarterly & annually)
How has GLUE ROE performed in the past?
The mean historical ROE of Monte Rosa Therapeutics, Inc. over the last ten years is -6.62%. The current -40.99% ROE has changed 519.29% with respect to the historical average. Over the past ten years (40 quarters), GLUE's ROE was at its highest in in the December 2020 quarter at 40.34%. The ROE was at its lowest in in the March 2020 quarter at -63.25%.
Average
-6.62%
Median
-21.28%
Minimum
-75.51%
Maximum
73.63%
Monte Rosa Therapeutics, Inc. (GLUE) ROE by Quarter and Year
Discovering the peaks and valleys of Monte Rosa Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 88.89%
Maximum Annual ROE = 73.63%
Minimum Annual Increase = -128.90%
Minimum Annual ROE = -75.51%
| Year | ROE | Change |
|---|---|---|
| 2025 | -16.57% | -49.18% |
| 2024 | -32.61% | -56.81% |
| 2023 | -75.51% | 88.89% |
| 2022 | -39.98% | 87.84% |
| 2021 | -21.28% | -128.90% |
| 2020 | 73.63% | 11.57% |
Monte Rosa Therapeutics, Inc. (GLUE) Average ROE
How has GLUE ROE performed in the past?
The current ROE of Monte Rosa Therapeutics, Inc. (GLUE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-41.56%
5-year avg
-37.19%
10-year avg
-6.62%
Monte Rosa Therapeutics, Inc. (GLUE) ROE vs. Peers
How is GLUE’s ROE compared to its peers?
Monte Rosa Therapeutics, Inc.’s ROE is greater than Day One Biopharmaceuticals, Inc. (-23.43%), greater than Arvinas, Inc. (-44.39%), greater than Replimune Group, Inc. (-102.69%), less than Theravance Biopharma, Inc. (43.85%), greater than ArriVent BioPharma, Inc. Common Stock (-48.98%), greater than Geron Corporation (-28.90%), greater than Vir Biotechnology, Inc. (-53.31%), greater than Ginkgo Bioworks Holdings, Inc. (-57.31%), greater than Valneva SE (-106.22%), less than MeiraGTx Holdings plc (474.91%),
| Company | ROE | Market cap |
|---|---|---|
| -23.43% | $2.22B | |
| -44.39% | $494.88M | |
| -102.69% | $841.41M | |
| 43.85% | $854.75M | |
| -48.98% | $1.48B | |
| -28.90% | $808.32M | |
| -53.31% | $1.54B | |
| -57.31% | $599.03M | |
| -106.22% | $510.15M | |
| 474.91% | $1.05B |
Build a custom stock screener for Monte Rosa Therapeutics, Inc. (GLUE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monte Rosa Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Monte Rosa Therapeutics, Inc. (GLUE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Monte Rosa Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Monte Rosa Therapeutics, Inc.'s ROE?
How is the ROE calculated for Monte Rosa Therapeutics, Inc. (GLUE)?
What is the highest ROE for Monte Rosa Therapeutics, Inc. (GLUE)?
What is the 3-year average ROE for Monte Rosa Therapeutics, Inc. (GLUE)?
What is the 5-year average ROE for Monte Rosa Therapeutics, Inc. (GLUE)?
How does the current ROE for Monte Rosa Therapeutics, Inc. (GLUE) compare to its historical average?